221 243

Cited 5 times in

Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension.

Authors
 Song-Yi Kim  ;  Seung-Jae Joo  ;  Mi-Seung Shin  ;  Changsoo Kim  ;  Eun Joo Cho  ;  Ki-Chul Sung  ;  Seok-Min Kang  ;  Dong-Soo Kim  ;  Seung Hwan Lee  ;  Kyung-Kuk Hwang  ;  Jeong Bae Park 
Citation
 MEDICINE, Vol.95(22) : 3764, 2016 
Journal Title
 MEDICINE 
ISSN
 0025-7974 
Issue Date
2016
MeSH
Adult ; Aged ; Ambulatory Care Facilities/statistics & numerical data ; Angiotensin Receptor Antagonists/adverse effects ; Angiotensin Receptor Antagonists/therapeutic use* ; Antihypertensive Agents/adverse effects ; Antihypertensive Agents/therapeutic use* ; Biphenyl Compounds/adverse effects ; Biphenyl Compounds/therapeutic use* ; Blood Pressure/drug effects ; Blood Pressure Monitoring, Ambulatory/statistics & numerical data ; Female ; Hospitals, University ; Humans ; Hypertension/drug therapy* ; Middle Aged ; Postmenopause* ; Prospective Studies ; Pulse ; Pyrimidines/adverse effects ; Pyrimidines/therapeutic use* ; Republic of Korea ; Tetrazoles/adverse effects ; Tetrazoles/therapeutic use*
Abstract
Angiotensin receptor blockers may be an appropriate first-line agent for postmenopausal women with hypertension because the activation of renin-angiotensin-aldosterone system is suggested as one possible mechanism of postmenopausal hypertension. However, there are few studies substantiating this effect. This study aimed to investigate clinic and home blood pressure (BP) lowering effect of fimasartan, a new angiotensin receptor blocker, in postmenopausal women with hypertension.Among patients with hypertension enrolled in K-Mets Study, 1373 women with fimasartan as a first antihypertensive drug and 3-months follow-up data were selected. They were divided into 2 groups; premenopausal women (pre-MPW; n = 382, 45.3 ± 4.6 years) and postmenopausal women (post-MPW; n = 991, 60.9 ± 8.2 years).Baseline clinic systolic BP was not different (pre-MPW; 152.9 ± 15.2 vs. post-MPW; 152.8 ± 13.5 mm Hg), but diastolic BP was lower in post-MPW (pre-MPW; 95.7 ± 9.4 vs. post-MPW; 91.9 ± 9.4 mm Hg, P <0.001). After 3-month treatment, clinic BP declined effectively without significant differences between 2 groups (Δsystolic/diastolic BP: pre-MPW; -25.7 ± 17.7/-14.2 ± 11.3 vs. post-MPW; -25.7 ± 16.3/-13.1 ± 10.9 mm Hg). Home morning and evening systolic BP decreased similarly in both groups (Δmorning/evening systolic BP: pre-MPW; -21.3 ± 17.9/-23.1 ± 15.8 vs. post-MPW; -20.4 ± 17.3/-20.2 ± 19.2 mm Hg). Fimasartan also significantly decreased the standard deviations of home morning and evening systolic BP of pre-MPW and post-MPW.Fimasartan was a similarly effective BP lowering agent in both post-MPW and pre-MPW with hypertension, and it also decreased day-to-day BP variability.
Files in This Item:
T201602211.pdf Download
DOI
10.1097/MD.0000000000003764
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine and Public Health (예방의학교실) > 1. Journal Papers
Yonsei Authors
Kang, Seok Min(강석민) ORCID logo https://orcid.org/0000-0001-9856-9227
Kim, Chang Soo(김창수) ORCID logo https://orcid.org/0000-0002-5940-5649
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/147145
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse